Research programme: antibody-drug conjugates - Ambrx/Astellas Pharma
Latest Information Update: 26 Nov 2015
At a glance
- Originator Ambrx
- Developer Agensys; Ambrx
- Class Drug conjugates; Immunoconjugates
- Mechanism of Action
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cancer
Most Recent Events
- 26 Nov 2015 Preclinical trials in Cancer in USA (Parenteral)
- 26 Nov 2015 Ambrx pipeline - Added Agensys as a licensee. Changed the role of Astellas Pharma from "Originator" to "Licensee" , and made it inactive because Ambrx pipeline states Agensys. Progressed to preclinical dev.
- 04 Apr 2013 Early research in Cancer in USA (Parenteral)